RT Journal Article
SR Electronic
T1 Multiomic Analyses Direct Hypotheses for Creutzfeldt-Jakob Disease Risk Genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.19.24310476
DO 10.1101/2024.07.19.24310476
A1 Küçükali, Fahri
A1 Hill, Elizabeth
A1 Watzeels, Tijs
A1 Hummerich, Holger
A1 Campbell, Tracy
A1 Darwent, Lee
A1 Collins, Steven
A1 Stehmann, Christiane
A1 Kovacs, Gabor G
A1 Geschwind, Michael D
A1 Frontzek, Karl
A1 Budka, Herbert
A1 Gelpi, Ellen
A1 Aguzzi, Adriano
A1 van der Lee, Sven J
A1 van Duijn, Cornelia M
A1 Liberski, Pawel P
A1 Calero, Miguel
A1 Sanchez-Juan, Pascual
A1 Bouaziz-Amar, Elodie
A1 Laplanche, Jean-Louis
A1 Haïk, Stéphane
A1 Brandel, Jean-Phillipe
A1 Mammana, Angela
A1 Capellari, Sabina
A1 Poleggi, Anna
A1 Ladogana, Anna
A1 Pocchiari, Maurizio
A1 Zafar, Saima
A1 Booth, Stephanie
A1 Jansen, Gerard H
A1 Areškevičiūtė, Aušrinė
A1 Lund, Eva Løbner
A1 Glisic, Katie
A1 Parchi, Piero
A1 Hermann, Peter
A1 Zerr, Inga
A1 Safar, Jiri
A1 Gambetti, Pierluigi
A1 Appleby, Brian S
A1 Collinge, John
A1 Sleegers, Kristel
A1 Mead, Simon
YR 2024
UL http://medrxiv.org/content/early/2024/07/21/2024.07.19.24310476.abstract
AB Prions are assemblies of misfolded prion protein that cause several fatal and transmissible neurodegenerative diseases, with the most common phenotype in humans being sporadic Creutzfeldt-Jakob disease (sCJD). Aside from variation of the prion protein itself, molecular risk factors are not well understood. Prion and prion-like mechanisms are thought to underpin common neurodegenerative disorders meaning that the elucidation of mechanisms could have broad relevance. Herein we sought to further develop our understanding of the factors that confer risk of sCJD using a systematic gene prioritization and functional interpretation pipeline based on multiomic integrative analyses. We integrated the published sCJD genome-wide association study (GWAS) summary statistics with publicly available bulk brain and brain cell type gene and protein expression datasets. We performed multiple transcriptome and proteome-wide association studies (TWAS & PWAS) and Bayesian genetic colocalization analyses between sCJD risk association signals and multiple brain molecular quantitative trait loci signals. We then applied our systematic gene prioritization pipeline on the obtained results and nominated prioritized sCJD risk genes with risk-associated molecular mechanisms in a transcriptome and proteome-wide manner. Genetic upregulation of both gene and protein expression of syntaxin-6 (STX6) in the brain was associated with sCJD risk in multiple datasets, with a risk-associated gene expression regulation specific to oligodendrocytes. Similarly, increased gene and protein expression of protein disulfide isomerase family A member 4 (PDIA4), involved in the unfolded protein response, was linked to increased disease risk, particularly in excitatory neurons. Protein expression of mesencephalic astrocyte derived neurotrophic factor (MANF), involved in protection against endoplasmic reticulum stress and sulfatide binding (linking to the enzyme in the final step of sulfatide synthesis, encoded by sCJD risk gene GAL3ST1), was identified as protective against sCJD. In total 32 genes were prioritized into two tiers based on level of evidence and confidence for further studies. This study provides insights into the genetically-associated molecular mechanisms underlying sCJD susceptibility and prioritizes several specific hypotheses for exploration beyond the prion protein itself and beyond the previously highlighted sCJD risk loci through the newly prioritized sCJD risk genes and mechanisms. These findings highlight the importance of glial cells, sulfatides and the excitatory neuron unfolded protein response in sCJD pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by the Medical Research Council (UK). SM and JC are National Institute for Health Research (NIHR) Senior Investigators. FK receives a postdoctoral fellowship (BOF 49758) from the University of Antwerp Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://adknowledgeportal.org The sCJD GWAS summary statistics is available at the European Bioinformatics Institute GWAS Catalog portal (https://www.ebi.ac.uk/gwas/) under accession no. GCST90001389. SEA-AD brain single nucleus gene expression matrices (https://registry.opendata.aws/allen-sea-ad-atlas/) eQTLs and TWAS reference panels in AD-relevant bulk brain regions from AMP-AD cohorts, as analyzed by Bellenguez et al.: (https://doi.org/10.5281/zenodo.5745927); GTEx v8 eQTL catalogues (https://www.gtexportal.org/); GTEx v8 MASHR expression prediction models for TWAS (https://predictdb.org/post/2021/07/21/gtex-v8-models-on-eqtl-and-sqtl/#mashr-based-models); Bryois et al. ct-eQTL catalogues (https://doi.org/10.5281/zenodo.5543734); MiGA eQTL catalogues (https://doi.org/10.5281/zenodo.4118605 and https://doi.org/10.5281/zenodo.4118676); Wingo et al. v2 pQTL catalogues & PWAS reference panels (https://www.synapse.org/#!Synapse:syn23627957). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes